May 9
ATOS · Atossa Therapeutics, Inc. · Documents
$1.65
-0.10 (-5.71%)
At close · Nov 20
Return incl. dividend (before tax)
Q2 2023 earnings call transcript
Going-concern doubt
— flagged Nov 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Nov 10, 2026
Market Cap
$15.92M
Shares
9.98M
Volume · Nov 20
48.93K
Avg daily vol (3M)
67.59K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2022
Apr 11
Proxy statement
DEF 14A
Meeting May 13, 2022
Proxy statement
Apr 1
Proxy statement
PRE 14A
Meeting May 13, 2022
Proxy statement
Feb 28
Current report
8-K
Events of Feb 24
Financial results, Director or officer change, or executive pay
Feb 28
2021
Nov 15
Current report
8-K
Financial results
Nov 15
Oct 6
Current report
8-K
Shareholder vote results
Sep 14
Proxy statement
DEFA14A
Proxy statement
Sep 8
Current report
8-K
Events of Sep 7
Shareholder vote results
Aug 13
Current report
8-K
Financial results
Aug 13
Aug 9
Proxy statement
DEF 14A
Meeting Sep 7, 2021
Proxy statement
Jul 29
Proxy statement
PRE 14A
Meeting Sep 7, 2021
Proxy statement
May 18
Current report
8-K
Events of May 14
Director or officer change, or executive pay, Shareholder vote results
May 14
Current report
8-K
Financial results
May 14
May 11
Proxy statement
DEFA14A
Proxy statement
Apr 21
Registration statement
S-3
Registration statement
Apr 15
Proxy statement
DEF 14A
Meeting May 14, 2021
Proxy statement
Apr 5
Proxy statement
PRE 14A
Meeting May 14, 2021
Proxy statement
Mar 31
Current report
8-K
Financial results
Mar 31
Mar 23
Current report
8-K
Events of Mar 22
Entered into a material agreement
Mar 22
Current report
8-K
Ended a material agreement
Jan 22
Registration statement
S-3
Registration statement
Jan 8
Current report
8-K
Events of Jan 6
Entered into a material agreement
2020
Dec 21
Current report
8-K
Events of Dec 17
Entered into a material agreement
Dec 14
Current report
8-K
Events of Dec 8
Entered into a material agreement
Dec 8
Current report
8-K
Current report
Dec 1
Registration statement
S-1/A
Registration statement
Nov 30
Current report
8-K
Events of Nov 26
Other events
Nov 20
Registration statement
S-1
Registration statement
Nov 13
Current report
8-K
Financial results
Nov 13
Sep 25
Current report
8-K
Entered into a material agreement
Sep 2
Registration statement
S-3
Registration statement
Aug 13
Current report
8-K
Financial results
Aug 13
May 19
Current report
8-K
Events of May 15
Shareholder vote results
May 13
Current report
8-K
Financial results
May 13
Apr 13
Proxy statement
DEF 14A
Meeting May 15, 2020
Proxy statement
Apr 13
Current report
8-K
Events of Apr 9
Director or officer change, or executive pay
Mar 26
Current report
8-K
Financial results
Mar 26
Feb 10
Current report
8-K
Events of Feb 7
Entered into a material agreement
Jan 7
Current report
8-K
Events of Jan 6
Charter or bylaw amendment, or fiscal year change
Showing 101–148 of 148 documents
Key facts
CIK
1488039
CUSIP
04962H704
13F (30d)
61 filings
35 filers
Visit website
Investor relations